{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:04:21Z","timestamp":1776261861620,"version":"3.50.1"},"reference-count":36,"publisher":"Japan Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1507\/endocrj.ej15-0362","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T17:13:28Z","timestamp":1450977208000},"page":"249-255","source":"Crossref","is-referenced-by-count":21,"title":["Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism"],"prefix":"10.1507","volume":"63","author":[{"given":"Yayoi","family":"Matsuda","sequence":"first","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"},{"name":"Division of Hepatology, Diabetes, Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaya","family":"Kawate","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"},{"name":"Graduate School of Health and Nutrition Sciences, Nakamura Gakuen University, Fukuoka 814-0198, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitose","family":"Matsuzaki","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"},{"name":"Department of Metabolism and Endocrinology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka 810-8563, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimitaka","family":"Shibue","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Ohnaka","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Anzai","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Diabetes, Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Takayanagi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Mattsson C, Young WF Jr (2006) Primary aldosteronism: diagnostic and treatment strategies. <i>Nat Clin Pract Nephrol<\/i> 2: 198-208.","DOI":"10.1038\/ncpneph0151"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab<\/i> 93: 3266-3281.","DOI":"10.1210\/jc.2008-0104"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC (1994) High incidence of primary aldosteronism in 199 patients referred with hypertension. <i>Clin Exp Pharmacol Physiol<\/i> 21: 315-318.","DOI":"10.1111\/j.1440-1681.1994.tb02519.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Schwartz GL, Turner ST (2005) Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. <i>Clin Chem<\/i> 51: 386-394.","DOI":"10.1373\/clinchem.2004.041780"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, et al. (2006) PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. <i>J Am Coll Cardiol<\/i> 48: 2293-2300.","DOI":"10.1016\/j.jacc.2006.07.059"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mosso L, Carvajal C, Gonz&aacute;lez A, Barraza A, Avila F, et al. (2003) Primary aldosteronism and hypertensive disease. <i>Hypertension<\/i> 42: 161-165.","DOI":"10.1161\/01.HYP.0000079505.25750.11"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr (2003) Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. <i>J Hum Hypertens<\/i> 17: 349-352.","DOI":"10.1038\/sj.jhh.1001554"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. <i>J Am Coll Cardiol <\/i>45: 1243-1248.","DOI":"10.1016\/j.jacc.2005.01.015"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, et al. (2009) Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn&rsquo;s Registry. <i>J Clin Endocrinol Metab<\/i> 94: 1125-1130.","DOI":"10.1210\/jc.2008-2116"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, et al. (2008) Cardiovascular outcomes in patients with primary aldosteronism after treatment. <i>Arch Intern Med<\/i> 168: 80-85.","DOI":"10.1001\/archinternmed.2007.33"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Strauch B, Petr&aacute;k O, Wichterle D, Zelinka T, Holaj R, et al. (2006) Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. <i>Am J Hypertens<\/i> 19: 909-914.","DOI":"10.1016\/j.amjhyper.2006.02.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Rizzoni D, Paiardi S, Rodella L, Porteri E, De Ciuceis C, et al. (2006) Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. <i>J Clin Endocrinol Metab<\/i> 91: 2638-2642.","DOI":"10.1210\/jc.2006-0101"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Holaj R, Zelinka T, Wichterle D, Petr&aacute;k O, Strauch B, et al. (2007) Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. <i>J Hypertens<\/i> 25: 1451-1457.","DOI":"10.1097\/HJH.0b013e3281268532"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, et al. (2008) Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. <i>J Hypertens<\/i> 26: 2399-2405.","DOI":"10.1097\/HJH.0b013e32831286fd"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tsuchiya K, Yoshimoto T, Hirata Y (2009) Endothelial dysfunction is related to aldosterone excess and raised blood pressure. <i>Endocr J<\/i> 56: 553-559.","DOI":"10.1507\/endocrj.K09E-014"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Widimsky J Jr, Strauch B, Petr&aacute;k O, Rosa J, Somloova Z, et al. (2012) Vascular disturbances in primary aldosteronism: clinical evidence. <i>Kidney Blood Press Res<\/i> 35: 529-533.","DOI":"10.1159\/000340031"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lin YH, Lin LY, Chen A, Wu XM, Lee JK (2012) Adrenalectomy improves increased carotid intima-media thickness (IMT) and arterial stiffness in patients with aldosterone producing adenoma. <i>Atherosclerosis<\/i> 221: 154-159.","DOI":"10.1016\/j.atherosclerosis.2011.12.003"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, et al. (2011) Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. <i>Endocr J<\/i> 58: 711-721.","DOI":"10.1507\/endocrj.EJ11-0133"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yanase T, Nasu Y, Mukuta Y, Shimizu Y, Nishihara T, et al. (2006) Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. <i>Am J Hypertens<\/i> 19: 1206-1212.","DOI":"10.1016\/j.amjhyper.2006.05.010"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Matsuda Y, Kawate H, Matsuzaki C, Sakamoto R, Abe I, et al. (2013) Reduced arterial stiffness in patients with acromegaly: non-invasive assessment by the cardio-ankle vascular index (CAVI). <i>Endocr J<\/i> 60: 29-36.","DOI":"10.1507\/endocrj.EJ12-0189"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kawate H, Kohno M, Matsuda Y, Akehi Y, Tanabe M, et al. (2014) Long-Term study of subclinical Cushing&rsquo;s syndrome shows high prevalence of extra-adrenal malignancy in patients with functioning bilateral adrenal tumors. <i>Endocr J<\/i> 61: 1205-1212.","DOI":"10.1507\/endocrj.EJ14-0155"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P (2002) Mineralocorticoid receptor antagonism in experimental atherosclerosis. <i>Circulation<\/i> 105: 2212-2216.","DOI":"10.1161\/01.CIR.0000015854.60710.10"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, et al. (2007) Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. <i>Nat Med<\/i> 13: 189-197.","DOI":"10.1038\/nm1545"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. <i>Nat Rev Nephrol<\/i> 9: 459-469.","DOI":"10.1038\/nrneph.2013.110"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Holaj R, Rosa J, Zelinka T, Strauch B, Petr&aacute;k O, et al. (2015) Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness. <i>J Hypertens<\/i> 33: 874-882.","DOI":"10.1097\/HJH.0000000000000464"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, et al. (2008) Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. <i>Expert Opin Pharmacother<\/i> 9: 509-515.","DOI":"10.1517\/14656566.9.4.509"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Parthasarathy HK, M&eacute;nard J, White WB, Young WF Jr, Williams GH, et al. (2011) A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. <i>J Hypertens<\/i> 29: 980-990.","DOI":"10.1097\/HJH.0b013e3283455ca5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Colussi G, Catena C, Sechi LA (2013) Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. <i>J Hypertens<\/i> 31: 3-15.","DOI":"10.1097\/HJH.0b013e3283599b6a"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. <i>Circulation<\/i> 115: 459-467.","DOI":"10.1161\/CIRCULATIONAHA.106.628875"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, et al. (2012) Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. <i>Cerebrovasc Dis<\/i> 34: 290-296.","DOI":"10.1159\/000343145"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. van den Oord SC, Sijbrands EJ, ten Kate GL, van Klaveren D, van Domburg RT, et al. (2013) Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis. <i>Atherosclerosis<\/i> 228: 1-11.","DOI":"10.1016\/j.atherosclerosis.2013.01.025"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Young MJ (2008) Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. <i>Curr Opin Nephrol Hypertens<\/i> 17: 174-180.","DOI":"10.1097\/MNH.0b013e3282f56854"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Jansen PM, Danser AH, Imholz BP, van den Meiracker AH (2009) Aldosterone-receptor antagonism in hypertension. <i>J Hypertens<\/i> 27: 680-691.","DOI":"10.1097\/HJH.0b013e32832810ed"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Colussi G, Catena C, Sechi LA (2013) Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. <i>J Hypertens<\/i> 31: 3-15.","DOI":"10.1097\/HJH.0b013e3283599b6a"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. <i>N Engl J Med<\/i> 341: 709-717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. <i>N Engl J Med<\/i> 348: 1309-1321.","DOI":"10.1056\/NEJMoa030207"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/63\/3\/63_EJ15-0362\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T19:27:55Z","timestamp":1567452475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/63\/3\/63_EJ15-0362\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej15-0362","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}